A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts.

Launched by THE FOURTH AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for plantar warts, which are small growths that usually appear on the soles of the feet. The researchers want to find out how effective bleomycin (a medication) and cryotherapy (freezing the warts) are in treating these warts. They will also look at how safe these treatments are, how much they cost, and how they affect patients' quality of life. Currently, they are looking for participants aged 18 to 65 who have plantar warts and are willing to volunteer for the study.

If you decide to join the trial, you will receive one of the two treatments and will be monitored throughout the process. Participants will need to sign a consent form and agree to have pictures taken of their warts. However, there are certain criteria that disqualify some people, such as those who have had recent treatments for warts, are pregnant, or have specific health conditions like HIV or severe immune issues. Overall, this trial aims to help improve the treatment options for plantar warts and better understand how these treatments work for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-65 years old, gender is not limited; Consistent with the diagnosis of plantar warts; Volunteer for treatment and sign informed consent; Consent to photograph the lesion; The treatment target area can be selected (the target area must meet the following conditions: The distance between adjacent warts in the target area is \>0.5cm; The diameter of a single wart in the target area is ≤1.5cm, and/or the diameter of a wart mass is ≤1.5cm; The number of total warts/wart masses in the target area is ≤10).
• Exclusion Criteria:
• • Patients who can't sign informed consent; Had previously received local treatment for common warts within 1 month; hiv-positive patient; Pregnant and lactating women; Has peripheral vascular disease; Allergic to bleomycin; People who are severely immunocompromised, or who are taking immunosuppressive drugs; Mental illness or cognitive incapacity; Other conditions deemed unsuitable for inclusion, such as inability to cooperate with follow-up, were considered by the researchers.